Biocryst Pharmaceuticals (BCRX) Other Operating Expenses (2012 - 2026)

Biocryst Pharmaceuticals' Other Operating Expenses history runs 15 years deep, the most recent figure standing at $703.1 million for Q1 2026.

• Quarterly Other Operating Expenses rose 15292.69% year-over-year to $703.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $717.6 million (up 4508.56% YoY) and the FY2025 annual result came in at $19.1 million, up 55.47% from the prior year.
• Other Operating Expenses was $703.1 million for Q1 2026 at Biocryst Pharmaceuticals, up from $9.5 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $703.1 million in Q1 2026 and bottomed at $238000.0 in Q1 2022.
• A 5-year average of $43.9 million and a median of $2.2 million in 2025 frame the typical range for Other Operating Expenses.
• Annual changes were most pronounced in 2022 — Other Operating Expenses plunged 95.96% — and 2026, when it jumped 15292.69%.
• Biocryst Pharmaceuticals' Other Operating Expenses stood at $2.5 million in 2022, then tumbled by 41.63% to $1.5 million in 2023, then soared by 318.26% to $6.1 million in 2024, then surged by 56.25% to $9.5 million in 2025, then surged by 7284.35% to $703.1 million in 2026.
• Business Quant data shows BCRX's Other Operating Expenses at $703.1 million in Q1 2026, $9.5 million in Q4 2025, and $2.2 million in Q3 2025.